Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway

Abstract. Background. Excessive inflammatory responses play a critical role in the development of severe acute pancreatitis (SAP), and controlling such inflammation is vital for managing this often fatal disease. Dexmedetomidine has been reported to possess protective properties in inflammatory dise...

Full description

Bibliographic Details
Main Authors: Dong-Ya Huang, Qiang Li, Chen-Yuan Shi, Chao-Qun Hou, Yi Miao, Hong-Bing Shen, Yuan-Yuan Ji
Format: Article
Language:English
Published: Wolters Kluwer 2020-05-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000000766
id doaj-7045b62a730b45b9988ce995d6abcc0b
record_format Article
spelling doaj-7045b62a730b45b9988ce995d6abcc0b2020-12-02T07:57:48ZengWolters KluwerChinese Medical Journal0366-69992542-56412020-05-0113391073107910.1097/CM9.0000000000000766202005050-00011Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathwayDong-Ya HuangQiang LiChen-Yuan ShiChao-Qun HouYi MiaoHong-Bing ShenYuan-Yuan JiAbstract. Background. Excessive inflammatory responses play a critical role in the development of severe acute pancreatitis (SAP), and controlling such inflammation is vital for managing this often fatal disease. Dexmedetomidine has been reported to possess protective properties in inflammatory diseases. Therefore, this study aimed to investigate whether dexmedetomidine pre-treatment exerts an anti-inflammatory effect in rats with SAP induced by sodium taurocholate, and if so, to determine the potential mechanism. Methods. SAP was induced with sodium taurocholate. Rats received an intraperitoneal injection of dexmedetomidine 30 min before sodium taurocholate administration. α-bungarotoxin, a selective alpha-7 nicotinic acetylcholine receptor (α7nAchR) antagonist, was injected intra-peritoneally 30 min before dexmedetomidine administration. The role of the vagus nerve was evaluated by performing unilateral cervical vagotomy before the administration of dexmedetomidine. Efferent discharge of the vagal nerve was recorded by the BL-420F Data Acquisition & Analysis System. Six hours after onset, serum pro-inflammatory cytokine (tumor necrosis factor α [TNF-α] and interleukin 6 [IL-6]) levels and amylase levels were determined using an enzyme-linked immunosorbent assay and an automated biochemical analyzer, respectively. Histopathological changes in the pancreas were observed after hematoxylin and eosin staining and scored according to Schmidt criteria. Results. Pre-treatment with dexmedetomidine significantly decreased serum levels of TNF-α, IL-6, and amylase, strongly alleviating pathological pancreatic injury in the rat model of SAP (TNF-α: 174.2 ± 30.2 vs. 256.1±42.4 pg/ml; IL-6: 293.3 ± 46.8 vs. 421.7 ± 48.3 pg/ml; amylase: 2102.3 ± 165.3 vs. 3186.4 ± 245.2 U/L). However, the anti-inflammatory and pancreatic protective effects were abolished after vagotomy or pre-administration of α-bungarotoxin. Dexmedetomidine also significantly increased the discharge frequency and amplitude of the cervical vagus nerve in the SAP rat model (discharge frequency: 456.8 ± 50.3 vs. 332.4 ± 25.1 Hz; discharge amplitude: 33.4 ± 5.3 vs. 20.5 ± 2.9 μV). Conclusions. Dexmedetomidine administration attenuated the systemic inflammatory response and local pancreatic injury caused by SAP in rats through the cholinergic anti-inflammatory pathway involving vagus- and α7nAChR-dependent mechanisms.http://journals.lww.com/10.1097/CM9.0000000000000766
collection DOAJ
language English
format Article
sources DOAJ
author Dong-Ya Huang
Qiang Li
Chen-Yuan Shi
Chao-Qun Hou
Yi Miao
Hong-Bing Shen
Yuan-Yuan Ji
spellingShingle Dong-Ya Huang
Qiang Li
Chen-Yuan Shi
Chao-Qun Hou
Yi Miao
Hong-Bing Shen
Yuan-Yuan Ji
Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
Chinese Medical Journal
author_facet Dong-Ya Huang
Qiang Li
Chen-Yuan Shi
Chao-Qun Hou
Yi Miao
Hong-Bing Shen
Yuan-Yuan Ji
author_sort Dong-Ya Huang
title Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
title_short Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
title_full Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
title_fullStr Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
title_full_unstemmed Dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
title_sort dexmedetomidine attenuates inflammation and pancreatic injury in a rat model of experimental severe acute pancreatitis via cholinergic anti-inflammatory pathway
publisher Wolters Kluwer
series Chinese Medical Journal
issn 0366-6999
2542-5641
publishDate 2020-05-01
description Abstract. Background. Excessive inflammatory responses play a critical role in the development of severe acute pancreatitis (SAP), and controlling such inflammation is vital for managing this often fatal disease. Dexmedetomidine has been reported to possess protective properties in inflammatory diseases. Therefore, this study aimed to investigate whether dexmedetomidine pre-treatment exerts an anti-inflammatory effect in rats with SAP induced by sodium taurocholate, and if so, to determine the potential mechanism. Methods. SAP was induced with sodium taurocholate. Rats received an intraperitoneal injection of dexmedetomidine 30 min before sodium taurocholate administration. α-bungarotoxin, a selective alpha-7 nicotinic acetylcholine receptor (α7nAchR) antagonist, was injected intra-peritoneally 30 min before dexmedetomidine administration. The role of the vagus nerve was evaluated by performing unilateral cervical vagotomy before the administration of dexmedetomidine. Efferent discharge of the vagal nerve was recorded by the BL-420F Data Acquisition & Analysis System. Six hours after onset, serum pro-inflammatory cytokine (tumor necrosis factor α [TNF-α] and interleukin 6 [IL-6]) levels and amylase levels were determined using an enzyme-linked immunosorbent assay and an automated biochemical analyzer, respectively. Histopathological changes in the pancreas were observed after hematoxylin and eosin staining and scored according to Schmidt criteria. Results. Pre-treatment with dexmedetomidine significantly decreased serum levels of TNF-α, IL-6, and amylase, strongly alleviating pathological pancreatic injury in the rat model of SAP (TNF-α: 174.2 ± 30.2 vs. 256.1±42.4 pg/ml; IL-6: 293.3 ± 46.8 vs. 421.7 ± 48.3 pg/ml; amylase: 2102.3 ± 165.3 vs. 3186.4 ± 245.2 U/L). However, the anti-inflammatory and pancreatic protective effects were abolished after vagotomy or pre-administration of α-bungarotoxin. Dexmedetomidine also significantly increased the discharge frequency and amplitude of the cervical vagus nerve in the SAP rat model (discharge frequency: 456.8 ± 50.3 vs. 332.4 ± 25.1 Hz; discharge amplitude: 33.4 ± 5.3 vs. 20.5 ± 2.9 μV). Conclusions. Dexmedetomidine administration attenuated the systemic inflammatory response and local pancreatic injury caused by SAP in rats through the cholinergic anti-inflammatory pathway involving vagus- and α7nAChR-dependent mechanisms.
url http://journals.lww.com/10.1097/CM9.0000000000000766
work_keys_str_mv AT dongyahuang dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT qiangli dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT chenyuanshi dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT chaoqunhou dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT yimiao dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT hongbingshen dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
AT yuanyuanji dexmedetomidineattenuatesinflammationandpancreaticinjuryinaratmodelofexperimentalsevereacutepancreatitisviacholinergicantiinflammatorypathway
_version_ 1724407898874839040